-
Also known as
Cytokeratin 17
-
Other names
keratin, type I cytoskeletal 17; Keratin, type I cytoskeletal 17; keratin, type I cytoskeletal 17; 39.1; CK-17; keratin-17; cytokeratin-17; keratin 17 epitope S1; keratin 17 epitope S2; keratin 17 epitope S4; keratin 17; 39.1; Cytokeratin-17; CK-17; Keratin-17; K17
-
Category
Antibodies
-
Subcategory
Mnoclonal antibodies
-
Gene name
KRT17
-
Gene name synonims
N/A
-
Other gene names
KRT17; KRT17; PC; K17; PC2; PCHC1; CK-17; K17
-
Clonality
Monoclonal
-
Immunoglobulin isotype
IgG2b, kappa
-
Clone
E3
-
Host organism
Mouse (Mus musculus)
-
Species reactivity
Human (Homo sapiens), Rat (Rattus norvegicus), Cow, Goat, Pig.; Due to limited knowledge and inability for testing each and every species, the reactivity of the antibody may extend to other species which are not listed hereby.
-
Specificity and cross reactivity
Cytokeratin 17 (CK17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IFP's). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. CK17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to CK17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. CK17 is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as "epithelial stem cell" marker because CK17 Ab marks basal cell differentiation. CK17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK5&6, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. CK17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20% of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including anti-CK17. Also important is that cases of triple negative breast carcinoma with expression of CK17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually anti-CK17 and anti-MUC1 immunoreactivity represents pancreatobiliary subtype whereas anti-MUC2 and anti-CDX-2 positivity defines intestinal subtype.; Since it is not possible to test each and every species our knowledge on the corss reactivity of the antibodies is limited. This particular antibody might cross react with speacies outside of the listed ones.
-
Purification method
N/A
-
Form Appearance
N/A
-
Concentration
N/A
-
Storage and shipping
Store the antibody at +4C. Temperature variations in the range of 1 to 7 degrees Celsius are tolerable. We recommend NOT to freeze the antibody. Antibody is stable for 24 months.
-
Tested applications
ELISA (EIA), Flow Cytometry (FC/FACS), Immunofluorescence (IF), Immunoprecipitation (IP), Western Blot (WB), Immunohistology (IH)
-
Properties
If you buy Antibodies supplied by MBS Monoclonals they should be stored frozen at - 24°C for long term storage and for short term at + 5°C.
-
French translation
anticorps
